MarketCap
Inhibikase Therapeutics IKT
$ 1.51
-4.73%
Facebook
X
Telegram
Inhibikase Therapeutics Depreciation & Amortization | IKT
Annual Depreciation & Amortization Inhibikase Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 60.5 K | 26.3 K | 177 K | 6.72 K | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 177 K | 6.72 K | 67.7 K |
Quarterly Depreciation & Amortization Inhibikase Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.2 K | - | - | 23.7 K | 24.2 K | 12.7 K | - | 6.57 K | 6.57 K | 6.57 K | - | 6.57 K | 159 K | 5.04 K | - | 1.68 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 159 K | 1.68 K | 25.2 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Crinetics Pharmaceuticals
CRNX
|
3.9 M | $ 84.95 | 0.13 % | $ 7.99 B |  USA |
 |
Immunome
IMNM
|
2.47 M | $ 17.89 | -0.54 % | $ 1.56 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
502 K | - | -60.05 % | $ 125 K | USA |
 |
InMed Pharmaceuticals
INM
|
205 K | $ 1.57 | 9.03 % | $ 6.54 M |  Canada |
 |
Inovio Pharmaceuticals
INO
|
1.42 M | $ 0.88 | -1.82 % | $ 41.3 M | USA |
 |
Innoviva
INVA
|
26.3 M | $ 21.06 | 1.91 % | $ 1.42 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
12.9 M | $ 13.78 | -2.24 % | $ 4.92 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
10.8 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
67 K | - | - | $ 521 M | USA |
 |
Axon Enterprise
AXON
|
83.2 M | $ 424.81 | 1.06 % | $ 33.2 B | USA |
 |
Axcella Health
AXLA
|
412 K | - | -16.42 % | $ 249 M | USA |
 |
Keros Therapeutics
KROS
|
1.51 M | $ 11.35 | 0.62 % | $ 422 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
4.63 M | - | - | $ 2.02 B | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
33.8 M | $ 308.16 | 1.53 % | $ 5.96 B | USA |
 |
BridgeBio Pharma
BBIO
|
5.43 M | $ 68.11 | -0.65 % | $ 13 B | USA |
 |
Liquidia Corporation
LQDA
|
1.53 M | $ 43.75 | 2.58 % | $ 3.77 B | USA |
 |
Tyme Technologies
TYME
|
5.18 K | - | 8.07 % | $ 54 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
621 K | $ 1.46 | 2.81 % | $ 530 M | USA |
 |
Mustang Bio
MBIO
|
34 K | $ 0.36 | -1.89 % | $ 1.77 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
1.39 M | $ 7.88 | 3.01 % | $ 1.65 B | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
1.51 M | $ 437.59 | 0.77 % | $ 9.82 B | USA |
 |
Cyclerion Therapeutics
CYCN
|
65 K | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
325 K | $ 1.69 | -10.37 % | $ 96.1 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
24.2 M | $ 83.44 | 3.79 % | $ 4.19 B | USA |
 |
Aptevo Therapeutics
APVO
|
240 K | $ 1.49 | -7.45 % | $ 470 K | USA |
 |
MannKind Corporation
MNKD
|
12.3 M | $ 3.23 | 1.25 % | $ 987 M | USA |
 |
Marker Therapeutics
MRKR
|
2.79 M | $ 0.9 | -6.16 % | $ 13.8 M | USA |
 |
Maravai LifeSciences Holdings
MRVI
|
23.6 M | $ 7.5 | 3.69 % | $ 1.08 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
32 K | $ 1.66 | -2.92 % | $ 9.09 M | USA |
 |
Neurocrine Biosciences
NBIX
|
26 M | $ 145.91 | 2.25 % | $ 14.5 B | USA |
 |
Orgenesis
ORGS
|
2.09 M | - | -33.86 % | $ 61.2 M | USA |
 |
Biogen
BIIB
|
780 M | $ 252.25 | 0.62 % | $ 37 B | USA |
 |
Minerva Neurosciences
NERV
|
5.44 K | $ 2.2 | -4.35 % | $ 18.6 M | USA |
 |
Nektar Therapeutics
NKTR
|
1.03 M | $ 37.17 | -0.12 % | $ 627 M | USA |
 |
Nkarta
NKTX
|
9.2 M | $ 1.87 | 4.47 % | $ 138 M | USA |
 |
NanoViricides
NNVC
|
517 K | $ 1.37 | -2.14 % | $ 27.7 M | USA |
 |
Codiak BioSciences
CDAK
|
5.34 M | - | -55.98 % | $ 2.15 M | USA |
 |
Nurix Therapeutics
NRIX
|
8.74 M | $ 25.55 | 0.83 % | $ 2.21 B | USA |
 |
Kodiak Sciences
KOD
|
18.3 M | $ 89.5 | 2.13 % | $ 4.76 B | USA |
 |
Intellia Therapeutics
NTLA
|
9.77 M | $ 11.26 | 0.4 % | $ 1.22 B | USA |
 |
Novavax
NVAX
|
28 M | $ 9.4 | -3.14 % | $ 1.52 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
4.01 B | $ 61.57 | 0.15 % | $ 125 B | USA |
 |
NextCure
NXTC
|
2.2 M | $ 5.22 | 4.72 % | $ 14.8 M | USA |